Chronic heart damage following doxorubicin treatment is alleviated by lovastatin

Pharmacological Research

Volumn 91, Issue , 2015, Pages 47-56

  Henninger, Christian ^a   Huelsenbeck, Stefanie ^b   Wenzel, Philip ^b   Brand, Moritz ^b   Huelsenbeck, Johannes ^b   Schad, Arno ^b   Fritz, Gerhard ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Anthracyclines; Chronic cardiotoxicity; Doxorubicin; Mitochondrial hyperproliferation; Rho GTPases; Statins

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DOXORUBICIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN A1B; INTERLEUKIN 6; MESSENGER RNA; MEVINOLIN; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; HEAT SHOCK PROTEIN 70; HEAT-SHOCK PROTEIN 70.1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTRON MICROSCOPY; FEMALE; GENE EXPRESSION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART STRESS; MITOCHONDRION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; C57BL MOUSE; CARDIOTOXICITY; DNA DAMAGE; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; HEART MUSCLE; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CARDIOTOXICITY; CONNECTIVE TISSUE GROWTH FACTOR; DNA DAMAGE; DNA, MITOCHONDRIAL; DOXORUBICIN; FEMALE; FIBROSIS; GENE EXPRESSION PROFILING; HSP70 HEAT-SHOCK PROTEINS; INTERLEUKIN-6; LOVASTATIN; MICE, INBRED C57BL; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN;

EID: 84915795118     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.11.003     Document Type: Article

References (75)

1. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev 56 2004 185 229
2. L.C. Kremer, E.C. van Dalen, M. Offringa, J. Ottenkamp, and P.A. Voute Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study J Clin Oncol 19 2001 191 196
3. E.C. van Dalen, H.J. van der Pal, W.E. Kok, H.N. Caron, and L.C. Kremer Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study Eur J Cancer 42 2006 3191 3198
4. A.L. Ferreira, L.S. Matsubara, and B.B. Matsubara Anthracycline-induced cardiotoxicity Cardiovasc Hematol Agents Med Chem 6 2008 278 281
5. Y.L. Lyu, J.E. Kerrigan, C.P. Lin, A.M. Azarova, Y.C. Tsai, and Y. Ban Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane Cancer Res 67 2007 8839 8846
6. S. Fogli, P. Nieri, and M.C. Breschi The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage FASEB J 18 2004 664 675
7. D.M. Weinstein, M.J. Mihm, and J.A. Bauer Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice J Pharmacol Exp Ther 294 2000 396 401
8. M.P. Cole, L. Chaiswing, T.D. Oberley, S.E. Edelmann, M.T. Piascik, and S.M. Lin The protective roles of nitric oxide and superoxide dismutase in adriamycin-induced cardiotoxicity Cardiovasc Res 69 2006 186 197
9. L. Chaiswing, M.P. Cole, W. Ittarat, L.I. Szweda, D.K. St Clair, and T.D. Oberley Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity Mol Cancer Ther 4 2005 1056 1064
10. P. Pacher, L. Liaudet, P. Bai, J.G. Mabley, P.M. Kaminski, and L. Virag Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction Circulation 107 2003 896 904
11. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J Clin Oncol 26 2008 3777 3784
12. B.B. Hasinoff, and E.H. Herman Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc Toxicol 7 2007 140 144
13. T. Yan, S. Deng, A. Metzger, U. Godtel-Armbrust, A.C. Porter, and L. Wojnowski Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin Mol Cancer Ther 8 2009 1075 1085
14. T. Simunek, M. Sterba, O. Popelova, M. Adamcova, R. Hrdina, and V. Gersl Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron Pharmacol Rep 61 2009 154 171
15. S. Classen, S. Olland, and J.M. Berger Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187 Proc Natl Acad Sci U S A 100 2003 10629 10634
16. E. Willmore, F. Errington, M.J. Tilby, and C.A. Austin Formation and longevity of idarubicin-induced DNA topoisomerase ii cleavable complexes in k562 human leukaemia cells Biochem Pharmacol 63 2002 1807 1815
17. M. Marty, M. Espie, A. Llombart, A. Monnier, B.L. Rapoport, and V. Stahalova Multicenter randomized phase iii study of the cardioprotective effect of dexrazoxane (cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy Ann Oncol 17 2006 614 622
18. K.F. Hofland, A.V. Thougaard, M. Sehested, and P.B. Jensen Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin Clin Cancer Res 11 2005 3915 3924
19. W.L. Salzer, M. Devidas, W.L. Carroll, N. Winick, J. Pullen, and S.P. Hunger Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group Leukemia 24 2010 355 370
20. C.K. Tebbi, W.B. London, D. Friedman, D. Villaluna, P.A. De Alarcon, and L.S. Constine Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease J Clin Oncol 25 2007 493 500
21. Q. Zhou, and J.K. Liao Pleiotropic effects of statins - basic research and clinical perspectives Circ J 74 2010 818 826
22. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu Rev Pharmacol Toxicol 45 2005 89 118
23. G. Fritz Targeting the mevalonate pathway for improved anticancer therapy Curr Cancer Drug Targets 9 2009 626 638
24. A. Hall Rho GTPases and the actin cytoskeleton Science 279 1998 509 514
25. A.B. Jaffe, and A. Hall Rho gtpases in transformation and metastasis Adv Cancer Res 84 2002 57 80
26. F.M. Vega, and A.J. Ridley Rho GTPases in cancer cell biology FEBS Lett 582 2008 2093 2101
27. P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells Carcinogenesis 26 2005 883 891
28. B. Agarwal, S. Bhendwal, B. Halmos, S.F. Moss, W.G. Ramey, and P.R. Holt Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells Clin Cancer Res 5 1999 2223 2229
29. S. Rao, M. Lowe, T.W. Herliczek, and K. Keyomarsi Lovastatin mediated g1 arrest in normal and tumor breast cells is through inhibition of cdk2 activity and redistribution of p21 and p27, independent of p53 Oncogene 17 1998 2393 2402
30. W. Feleszko, I. Mlynarczuk, D. Olszewska, A. Jalili, T. Grzela, and W. Lasek Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism Int J Cancer 100 2002 111 118
31. W. Feleszko, and M. Jakobisiak Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells Clin Cancer Res 6 2000 1198 1199
32. J. Dimitroulakos, D. Nohynek, K.L. Backway, D.W. Hedley, H. Yeger, and M.H. Freedman Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach Blood 93 1999 1308 1318
33. J. Dimitroulakos, L.Y. Ye, M. Benzaquen, M.J. Moore, S. Kamel-Reid, and M.H. Freedman Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications Clin Cancer Res 7 2001 158 167
34. J. Damrot, T. Nuebel, B. Epe, W.P. Roos, B. Kaina, and G. Fritz Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide Br J Pharmacol 149 2006 988 997
35. T. Nuebel, J. Damrot, W.P. Roos, B. Kaina, and G. Fritz Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks Clin Cancer Res 12 2006 933 939
36. M. Mahmoudi, I. Gorenne, J. Mercer, N. Figg, T. Littlewood, and M. Bennett Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells Circ Res 103 2008 717 725
37. V. Haydont, C. Bourgier, M. Pocard, A. Lusinchi, J. Aigueperse, and D. Mathe Pravastatin inhibits the rho/ccn2/extracellular matrix cascade in human fibrosis explants and improves radiation-induced intestinal fibrosis in rats Clin Cancer Res 13 2007 5331 5340
38. V. Haydont, C. Bourgier, and M.C. Vozenin-Brotons Rho/rock pathway as a molecular target for modulation of intestinal radiation-induced toxicity Br J Radiol 80 2007 32 40
39. J. Huelsenbeck, C. Henninger, A. Schad, K.J. Lackner, B. Kaina, and G. Fritz Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity Cell Death Dis 2 2011 e190
40. A. Riad, S. Bien, D. Westermann, P.M. Becher, K. Loya, and U. Landmesser Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice Cancer Res 69 2009 695 699
41. M. Yoshida, I. Shiojima, H. Ikeda, and I. Komuro Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-atm-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of rac1 activity J Mol Cell Cardiol 47 2009 698 705
42. C. Henninger, J. Huelsenbeck, S. Huelsenbeck, S. Grosch, A. Schad, and K.J. Lackner The lipid lowering drug lovastatin protects against doxorubicin-induced hepatotoxicity Toxicol Appl Pharmacol 261 2012 66 73
43. M. Rashid, S. Tawara, Y. Fukumoto, M. Seto, K. Yano, and H. Shimokawa Importance of rac1 signaling pathway inhibition in the pleiotropic effects of HMG-CoA reductase inhibitors Circ J 73 2009 361 370
44. J. Ma, Y. Wang, D. Zheng, M. Wei, H. Xu, and T. Peng Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways Cardiovasc Res 97 2013 77 87
45. W. Feleszko, I. Mlynarczuk, E.Z. Balkowiec-Iskra, A. Czajka, T. Switaj, and T. Stoklosa Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice Clin Cancer Res 6 2000 2044 2052
46. S.C. Huelsenbeck, A. Schorr, W.P. Roos, J. Huelsenbeck, C. Henninger, and B. Kaina Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase ii poisons J Biol Chem 287 2012 38590 38599
47. D.A. Gewirtz A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin Biochem Pharmacol 57 1999 727 741
48. F.S. Carvalho, A. Burgeiro, R. Garcia, A.J. Moreno, R.A. Carvalho, and P.J. Oliveira Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy Med Res Rev 34 2014 106 135
49. E.L. De Beer, A.E. Bottone, and E.E. Voest Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review Eur J Pharmacol 415 2001 1 11
50. J. Kou, M. Song, A. Pattanayak, J.E. Lim, J. Yang, and D. Cao Combined treatment of abeta immunization with statin in a mouse model of Alzheimer's disease J Neuroimmunol 244 2012 70 83
51. J. Jawien, P. Nastalek, and R. Korbut Mouse models of experimental atherosclerosis J Physiol Pharmacol 55 2004 503 517
52. G. Fritz, C. Henninger, and J. Huelsenbeck Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents Br Med Bull 97 2011 17 26
53. X. Marechal, D. Montaigne, C. Marciniak, P. Marchetti, S.M. Hassoun, and J.C. Beauvillain Doxorubicin-induced cardiac dysfunction is attenuated by ciclosporin treatment in mice through improvements in mitochondrial bioenergetics Clin Sci (Lond) 121 2011 405 413
54. P.L. Olive Detection of DNA damage in individual cells by analysis of histone h2ax phosphorylation Methods Cell Biol 75 2004 355 373
55. D.A. Eppstein, C.G. Kurahara, N.A. Bruno, and T.G. Terrell Prevention of doxorubicin-induced hematotoxicity in mice by interleukin 1 Cancer Res 49 1989 3955 3960
56. D. Montaigne, X. Marechal, S. Preau, R. Baccouch, T. Modine, and G. Fayad Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium Mitochondrion 11 2011 22 26
57. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
58. M.W. Merx, E.A. Liehn, U. Janssens, R. Lutticken, J. Schrader, and P. Hanrath HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis Circulation 109 2004 2560 2565
59. A. Ludman, V. Venugopal, D.M. Yellon, and D.J. Hausenloy Statins and cardioprotection - more than just lipid lowering Pharmacol Ther 122 2009 30 43
60. C. Ostrau, J. Hulsenbeck, M. Herzog, A. Schad, M. Torzewski, and K.J. Lackner Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo Radiother Oncol 92 2009 492 499
61. V. Monceau, N. Pasinetti, C. Schupp, F. Pouzoulet, P. Opolon, and M.C. Vozenin Modulation of the rho/rock pathway in heart and lung after thorax irradiation reveals targets to improve normal tissue toxicity Curr Drug Targets 11 2010 1395 1404
62. J. Wang, M. Boerma, Q. Fu, A. Kulkarni, L.M. Fink, and M. Hauer-Jensen Simvastatin ameliorates radiation enteropathy development after localized, fractionated irradiation by a protein c-independent mechanism Int J Radiat Oncol Biol Phys 68 2007 1483 1490
63. K.E. Porter, and N.A. Turner Statins and myocardial remodelling: cell and molecular pathways Expert Rev Mol Med 13 2011 e22
64. N. Hermida, A. Markl, J. Hamelet, T. Van Assche, A. Vanderper, and P. Herijgers HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through amp-activated protein kinase activation in a mouse model of metabolic syndrome Cardiovasc Res 99 2013 44 54
65. J.T. Silver, and E.G. Noble Regulation of survival gene hsp70 Cell Stress Chaperones 17 2012 1 9
66. M. Daugaard, M. Rohde, and M. Jaattela The heat shock protein 70 family: highly homologous proteins with overlapping and distinct functions FEBS Lett 581 2007 3702 3710
67. J. Kluza, P. Marchetti, M.A. Gallego, S. Lancel, C. Fournier, and A. Loyens Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells Oncogene 23 2004 7018 7030
68. S. Zhang, X. Liu, T. Bawa-Khalfe, L.S. Lu, Y.L. Lyu, and L.F. Liu Identification of the molecular basis of doxorubicin-induced cardiotoxicity Nat Med 18 2012 1639 1642
69. P. Menna, E. Salvatorelli, and G. Minotti Doxorubicin degradation in cardiomyocytes J Pharmacol Exp Ther 322 2007 408 419
70. P. Menna, E. Salvatorelli, and G. Minotti Anthracycline degradation in cardiomyocytes: a journey to oxidative survival Chem Res Toxicol 23 2009 6 10
71. L. Woodbine, H. Brunton, A.A. Goodarzi, A. Shibata, and P.A. Jeggo Endogenously induced DNA double strand breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and artemis for their repair Nucleic Acids Res 39 2011 6986 6997
72. R. Colavitti, and T. Finkel Reactive oxygen species as mediators of cellular senescence IUBMB Life 57 2005 277 281
73. T. Shioi, and Y. Inuzuka Aging as a substrate of heart failure J Cardiol 60 2012 423 428
74. S.J. Cho, J.S. Kim, J.M. Kim, J.Y. Lee, H.C. Jung, and I.S. Song Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice Int J Cancer 123 2008 951 957
75. S. Seicean, A. Seicean, J.C. Plana, G.T. Budd, and T.H. Marwick Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study J Am Coll Cardiol 60 2012 2384 2390